Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis patients

Dupilumab suppressed cutaneous and systemic measures of inflammation while improving epidermal pathology and clinical disease-severity scores at 4 weeks (maximally at 16 weeks) in moderate-to-severe atopic dermatitis, confirming atopic dermatitis as a Type 2-driven disease.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2M1Eyqr